David John King

Title: David John King: Innovator in Antibody Technology

Introduction

David John King is a notable inventor based in Camberley, GB. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies and multivalent antigen-binding proteins. With a total of 2 patents to his name, his work has implications for the diagnosis and treatment of colorectal tumors.

Latest Patents

King's latest patents include innovative technologies such as humanized antibodies directed against the A33 antigen. These A33 antigen-binding proteins are designed for use in diagnosing or treating colorectal tumors and their metastases. The binding proteins may consist of humanized A33 antibodies, which can include complete antibody molecules and fragments, as well as multivalent monospecific proteins that are linked by a cross-linking agent. Additionally, the humanized A33 antibody can be connected to a reporter or effector molecule for enhanced diagnostic or therapeutic applications.

Another significant patent involves multivalent antigen-binding proteins. These proteins consist of a first Fv fragment that is bound to at least one additional Fv fragment through a connecting structure. This structure maintains the Fv fragments spaced apart, allowing them to bind to adjacent antigenic determinants. The connecting structure typically includes a spacing polypeptide sequence and a linkage unit, which can be a synthetic chemical linker or a polypeptide sequence. The proteins are primarily prepared using recombinant DNA techniques and are intended for in vivo therapeutic and diagnostic applications.

Career Highlights

David John King has established himself as a key figure in the biotechnology sector, particularly through his work at Celltech Limited. His innovative approaches to antibody technology have positioned him as a leader in the field, contributing to advancements that have the potential to improve patient outcomes in cancer treatment.

Collaborations

Throughout his career, King has collaborated with notable colleagues, including Raymond John Owens and John Robert Adair. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking technologies in the field of biotechnology.

Conclusion

David John King is a distinguished inventor whose work in antibody technology has made a significant impact on the field of biotechnology. His patents reflect a commitment to advancing medical science and improving therapeutic options for patients.